Cardiac Arrhythmia - An-Najah National University
... Cardiac Arrhythmia Arrhythmias: Abnormal rhythms of the heart that cause the heart to pump less effectively Arrhythmia occurs: ...
... Cardiac Arrhythmia Arrhythmias: Abnormal rhythms of the heart that cause the heart to pump less effectively Arrhythmia occurs: ...
Heart - Cloudfront.net
... • Tachycardia: Heart rate in excess of 100bpm • Bradycardia: Heart rate less than 60 bpm • Sinus arrhythmia: Heart rate varies 5% during respiratory cycle and up to 30% during deep respiration • Premature atrial contractions: Occasional shortened intervals between one contraction and succeeding, fre ...
... • Tachycardia: Heart rate in excess of 100bpm • Bradycardia: Heart rate less than 60 bpm • Sinus arrhythmia: Heart rate varies 5% during respiratory cycle and up to 30% during deep respiration • Premature atrial contractions: Occasional shortened intervals between one contraction and succeeding, fre ...
l-Transposition of the Great Arteries
... pressure may help with congestive heart failure symptoms. A pacemaker may be required in the event of abnormally slow heart rhythms. You should also consult a cardiologist with expertise in caring for adults with congenital heart disease if you are undergoing any type of non-heart surgery or invasiv ...
... pressure may help with congestive heart failure symptoms. A pacemaker may be required in the event of abnormally slow heart rhythms. You should also consult a cardiologist with expertise in caring for adults with congenital heart disease if you are undergoing any type of non-heart surgery or invasiv ...
INFECTIVE ENDOCARDITIS – A DISEASE NOT TO BE MISSED At
... • Early recognition and investigation is crucial • Blood cultures (ideally pre antibiotic therapy) • Early Echo (Transoesophageal ) ...
... • Early recognition and investigation is crucial • Blood cultures (ideally pre antibiotic therapy) • Early Echo (Transoesophageal ) ...
AED Safety Tip Flyer Final.pub - PMA
... Cardiovascular disease is the major cause of death in the United States. Nearly half of these deaths (250 000 to 500 000) are sudden and unexpected. Most of these sudden deaths occur outside the hospital and could occur at the workplace. Survival rates have traditionally been poor—only 1% to 5% of t ...
... Cardiovascular disease is the major cause of death in the United States. Nearly half of these deaths (250 000 to 500 000) are sudden and unexpected. Most of these sudden deaths occur outside the hospital and could occur at the workplace. Survival rates have traditionally been poor—only 1% to 5% of t ...
CorePace #5 - Pacemaker Basics
... • Potential complications include, but are not limited to, valve damage, fibrillation and other arrhythmias, thrombosis, thrombotic and air embolism, cardiac perforation, heart wall rupture, cardiac tamponade, muscle or nerve stimulation, pericardial rub, infection, myocardial irritability, and pneu ...
... • Potential complications include, but are not limited to, valve damage, fibrillation and other arrhythmias, thrombosis, thrombotic and air embolism, cardiac perforation, heart wall rupture, cardiac tamponade, muscle or nerve stimulation, pericardial rub, infection, myocardial irritability, and pneu ...
File - Kelly Marchant RN
... D. Administer Atropine 1mg IVP 11. A patient’s EKG demonstrates a rate of 35 and is in 2nd degree type II AV Block. The expected treatment for this patient would be A. Atropine 10 mg IVP B. Metoprolol 10 mg IVP C. Amlodipine 10 mg PO *D. Cardiac Pacemaker 12. During discharge teaching for a patient ...
... D. Administer Atropine 1mg IVP 11. A patient’s EKG demonstrates a rate of 35 and is in 2nd degree type II AV Block. The expected treatment for this patient would be A. Atropine 10 mg IVP B. Metoprolol 10 mg IVP C. Amlodipine 10 mg PO *D. Cardiac Pacemaker 12. During discharge teaching for a patient ...
TABLE OF CONTENTS
... meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or ...
... meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or ...
Heart Notes
... Gentamycin – ASA – increase clotting time. Given as prophylactic daily or 1st Aid for MI. ...
... Gentamycin – ASA – increase clotting time. Given as prophylactic daily or 1st Aid for MI. ...
Slides - American Heart Association
... treatment with carvedilol over metoprolol tartrate (short acting metoprolol) in patients with NYHA class II-IV and LVEF <35% • Comment: metoprolol succinate (long acting, i.e. Toprol XL) was not commercially available when this trial started ...
... treatment with carvedilol over metoprolol tartrate (short acting metoprolol) in patients with NYHA class II-IV and LVEF <35% • Comment: metoprolol succinate (long acting, i.e. Toprol XL) was not commercially available when this trial started ...
Levosimendan
... 4.4 Special warnings and special precautions for use An initial haemodynamic effect of levosimendan may be a decrease in systolic and diastolic blood pressure, therefore, levosimendan should be used with caution in patients with low baseline systolic or diastolic blood pressure or those at risk for ...
... 4.4 Special warnings and special precautions for use An initial haemodynamic effect of levosimendan may be a decrease in systolic and diastolic blood pressure, therefore, levosimendan should be used with caution in patients with low baseline systolic or diastolic blood pressure or those at risk for ...
the MADIT-RIT Programming Card
... These Boston Scientific Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) are indicated for patients with heart failure who receive stable optimal pharmacologic therapy (OPT) for heart failure and who meet any one of the following classifications: • Moderate to severe heart failure (NYHA Cla ...
... These Boston Scientific Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) are indicated for patients with heart failure who receive stable optimal pharmacologic therapy (OPT) for heart failure and who meet any one of the following classifications: • Moderate to severe heart failure (NYHA Cla ...
Acute Decompensated Heart Failure
... Describe the role of advanced cardiovascular therapies in patients with refractory acute decompensated heart failure, including temporary and durable mechanical circulatory support and cardiac transplantation. ...
... Describe the role of advanced cardiovascular therapies in patients with refractory acute decompensated heart failure, including temporary and durable mechanical circulatory support and cardiac transplantation. ...
Cardiovascular Physiology
... valves, vena cavas, pulmonary artery, pulmonary vein, aorta, coronary arteries, papillary muscle, chordae tendinea. Be able to describe the function of each. 2. Understand the mechanism of function of the cardiac valves. 3. Be able to trace the flow of blood through the heart. Know the saturation of ...
... valves, vena cavas, pulmonary artery, pulmonary vein, aorta, coronary arteries, papillary muscle, chordae tendinea. Be able to describe the function of each. 2. Understand the mechanism of function of the cardiac valves. 3. Be able to trace the flow of blood through the heart. Know the saturation of ...
1. Describe the cardiac conduction system and an ECG. Tell how an
... This bundle crosses the fibrous ring that separates atria and ventricles then, at the upper end of the ventricular septum, it divides into right and left bundle branches. These branches break up into fine fibres, called the ...
... This bundle crosses the fibrous ring that separates atria and ventricles then, at the upper end of the ventricular septum, it divides into right and left bundle branches. These branches break up into fine fibres, called the ...
ECG NOTES
... system it occurs when the atria get out of rhythm and shake instead of pumping • Atrial Fibrillation ...
... system it occurs when the atria get out of rhythm and shake instead of pumping • Atrial Fibrillation ...
Presentation TEMEO CARDIOLOGY TELEMETRIC SYSTEM
... • Prevention after hospitalization • Clinical examinations in Cardiology • Monitoring of elderly and disabled people • Rehabilitation ...
... • Prevention after hospitalization • Clinical examinations in Cardiology • Monitoring of elderly and disabled people • Rehabilitation ...
Chapter01_Detailed_Answers
... The electrocardiogram measures the heart’s electrical activity. The pulse strength is measured by taking the patient’s pulse while the blood pressure is measured with a sphygmomanometer. ...
... The electrocardiogram measures the heart’s electrical activity. The pulse strength is measured by taking the patient’s pulse while the blood pressure is measured with a sphygmomanometer. ...
Cardiac Cycle (PPT#4)
... ► Mid-to-late diastole (relaxation) = blood flows into ventricles ► Ventricular systole (contraction) = blood pressure builds before ventricles contract pushing blood out ► Early diastole = atria finish re-filling; ventricular pressure is low ...
... ► Mid-to-late diastole (relaxation) = blood flows into ventricles ► Ventricular systole (contraction) = blood pressure builds before ventricles contract pushing blood out ► Early diastole = atria finish re-filling; ventricular pressure is low ...
Cardiac Muscle
... • 5. The atriums pump and send blood down to the left ventricle • The left ventricle is the strongest part of the heart • 6. The ventricles then pump. This sends blood to the various parts of the body ...
... • 5. The atriums pump and send blood down to the left ventricle • The left ventricle is the strongest part of the heart • 6. The ventricles then pump. This sends blood to the various parts of the body ...
Full Text - Ibrahim Medical College
... with acute heart failure were enrolled. Out of 100 cases, 50 had elevated serum cTn-I (cTn-I 1.0 ng/ml) and 50 had normal serum cTn-I (cTn-I < 1.0 ng/ml). The adverse outcome of the two groups were recorded and compared. Patients with high and normal serum cTn-I had mean age of 52.40 ± 8.10 years ...
... with acute heart failure were enrolled. Out of 100 cases, 50 had elevated serum cTn-I (cTn-I 1.0 ng/ml) and 50 had normal serum cTn-I (cTn-I < 1.0 ng/ml). The adverse outcome of the two groups were recorded and compared. Patients with high and normal serum cTn-I had mean age of 52.40 ± 8.10 years ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.